Jan 8 (Reuters) - Scholar Rock Holding Corp SRRK.O:
SCHOLAR ROCK HIGHLIGHTS 2025 STRATEGIC PRIORITIES
SCHOLAR ROCK HOLDING CORP -FILING OF IND APPLICATION FOR SRK-439 ON TRACK FOR 3Q 2025
SCHOLAR ROCK HOLDING CORP - BLA AND MAA SUBMISSION FOR APITEGROMAB IN SMA ON TRACK FOR 1Q 2025
SCHOLAR ROCK HOLDING CORP - INITIATING PHASE 2 OPAL TRIAL IN SMA PATIENTS UNDER TWO YEARS OLD IN MID- 2025
SCHOLAR ROCK HOLDING CORP - DATA FROM PHASE 2 EMBRAZE TRIAL EXPECTED IN 2Q 2025
Source text: ID:nBwbcTM0Ha
Further company coverage: SRRK.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。